BC
NRIX icon

Boxer Capital’s Nurix Therapeutics NRIX Stock Holding History

Boxer Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-563,067
Closed -$12.7M – 33
2024
Q3 		$12.7M Buy
+563,067
New +$12.8M 0.62% 41
2023
Q4 		– Sell
-1,224,892
Closed -$9.63M – 64
2023
Q3 		$9.63M Hold
1,224,892
– – 0.51% 42
2023
Q2 		$12.2M Hold
1,224,892
– – 0.57% 45
2023
Q1 		$10.9M Hold
1,224,892
– – 0.53% 43
2022
Q4 		$13.4M Hold
1,224,892
– – 0.71% 39
2022
Q3 		$16M Hold
1,224,892
– – 0.9% 39
2022
Q2 		$15.5M Hold
1,224,892
– – 0.98% 35
2022
Q1 		$17.2M Hold
1,224,892
– – 0.88% 35
2021
Q4 		$35.5M Hold
1,224,892
– – 1.38% 20
2021
Q3 		$36.7M Hold
1,224,892
– – 1.28% 23
2021
Q2 		$32.5M Hold
1,224,892
– – 1.15% 24
2021
Q1 		$38.1M Hold
1,224,892
– – 1.29% 23
2020
Q4 		$40.3M Sell
1,224,892
-129,500
-10% -$4.29M 1.29% 23
2020
Q3 		$47.3M Buy
+1,354,392
New +$34.1M 1.63% 15

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital's NRIX Position: Q4 2024 in Review

Boxer Capital sold out of Nurix Therapeutics (NRIX) in Q4 2024, closing a stake of 563,067 shares — an estimated $12.7M sold.

Boxer Capital first reported a position in NRIX in Q3 2020 and held it in 14 quarters. The position peaked at $47.3M in Q3 2020. 175 funds tracked by Wall St. Rank hold NRIX as of Q4 2024.

  • Boxer Capital reported no remaining Nurix Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 563,067 Nurix Therapeutics shares in Q4 2024, an estimated $12.7M.
  • Boxer Capital first reported a position in Nurix Therapeutics in Q3 2020 and held it in 14 quarters.
  • Boxer Capital's Nurix Therapeutics position peaked at $47.3M in Q3 2020.
  • 175 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.